miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1
In conclusion, miR-539 increased the chemosensitivity to DDP in NSCLC cells by directly targeting DCLK1, which might provide potential biomarkers for DDP-resistant NSCLC therapy.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study